Bicycle Therapeutics picks up speed with $52M Series B
With a fresh financing from a Series B, Bicycle Therapeutics needs to begin translating its high-potential peptide-based platform into a portfolio of clinically-proven drugs.
Seattle Genetics signs $2B deal for solid tumor ADC
Seattle Genetics has secured global rights to Immunomedics' antibody-drug conjugate IMMU-132 (sacituzumab govitecan), currently in late-stage trials for triple-negative metastatic breast cancer. If the drug succeeds, the deal could be worth up to $2 billion.
presented by
3D Medical Animation Services: A Revolution in Healthcare Education and Marketing
3D medical animation services have emerged as a groundbreaking tool in the healthcare industry, revolutionizing the way medical concepts are taught, understood, and marketed.
Send in the Pentarins: Tarveda raises $30M Series D
Like deadly paratroopers descending from the skies, Tarveda's Pentarin drug conjugates are designed to infiltrate dense tumors, triggering a controlled cell death as they are internalized or bound. It's an ADC variation that's gaining momentum and cash.
Fatalities put Seattle Genetics’ trials on hold
Three out of five clinical trials evaluating Seattle Genetics' investigational ADC vadastuximab have ground to a halt after six adverse events and four fatalities were reported. No such toxicity has been reported in trials involving newly-diagnosed patients.